Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
Ritonavir (RTV) is a protease inhibitor (PI) commonly used to increase drug levels of other
PIs in HIV drug treatment. The purpose of this study is to compare a combination of drugs
which includes RTV and 2 protease inhibitors (PIs) with 2 combinations that include RTV and
another PI. This study also will compare the effectiveness, safety, tolerability, and drug
levels in the blood of these anti-HIV drug combinations.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)